Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06771115 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT06771115: Completed Phase 2 study, sponsored by Zomagen Biosciences.
NCT06771115 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 176 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06771115, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.
Primary Outcome
Incidence of AEs and SAEs and AEs leading to study treatment discontinuation
Interventions
- DRUG Placebo
- DRUG VTX3232 Dose A
- DRUG VTX3232 Dose A in combination with semaglutide
- DRUG Placebo in combination with semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 2 |
What the finished NCT06771115 record still lists
NCT06771115 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06771115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06771115 about?
NCT06771115 is a clinical study titled "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity". This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This stu...
What is the current status of trial NCT06771115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2025-01-07. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT06771115?
The interventions under investigation include: Placebo (DRUG), VTX3232 Dose A (DRUG), VTX3232 Dose A in combination with semaglutide (DRUG), Placebo in combination with semaglutide (DRUG).
Who is sponsoring clinical trial NCT06771115?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06771115's enrollment target sits among peer trials
176 394th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI